Emmaus Life Sciences, Inc. – OTC:EMMA
Emmaus Life Sciences stock price today
Emmaus Life Sciences stock price monthly change
Emmaus Life Sciences stock price quarterly change
Emmaus Life Sciences stock price yearly change
Emmaus Life Sciences key metrics
Market Cap | 20.06M |
Enterprise value | N/A |
P/E | -1.45 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 0.60 |
Price/Book | -0.46 |
PEG ratio | -0.04 |
EPS | -0.07 |
Revenue | 29.59M |
EBITDA | 3.09M |
Income | -3.73M |
Revenue Q/Q | 19.17% |
Revenue Y/Y | 60.94% |
Profit margin | -81.27% |
Oper. margin | -42.82% |
Gross margin | 84.6% |
EBIT margin | -42.82% |
EBITDA margin | 10.46% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEmmaus Life Sciences stock price history
Emmaus Life Sciences stock forecast
Emmaus Life Sciences financial statements
| Mar 2023 | 6.75M | -3.52M | -52.23% |
|---|---|---|---|
| Jun 2023 | 10.75M | -1.48M | -13.77% |
| Sep 2023 | 5.01M | 67K | 1.34% |
| Dec 2023 | 7.06M | 1.20M | 17.11% |
| 2025 | 30.14M | 2.96M | 9.84% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-11-14 | -0.03 | -0.01 |
|---|---|---|
| 2023-03-31 | 0.01 | 0.01 |
| Mar 2023 | 48946000 | 84.89M | 173.45% |
|---|---|---|---|
| Jun 2023 | 50288000 | 85.32M | 169.66% |
| Sep 2023 | 47453000 | 83.78M | 176.56% |
| Dec 2023 | 35179000 | 82.93M | 235.75% |
| Mar 2023 | -1.29M | -1.09M | 2.14M |
|---|---|---|---|
| Jun 2023 | -1.30M | 1.06M | -153K |
| Sep 2023 | 58K | -399K | 494K |
| Dec 2023 | 1.03M | -6K | -5K |
Emmaus Life Sciences alternative data
| Aug 2023 | 54 |
|---|---|
| Sep 2023 | 54 |
| Oct 2023 | 54 |
| Nov 2023 | 54 |
| Dec 2023 | 54 |
| Jan 2024 | 54 |
| Feb 2024 | 54 |
| Mar 2024 | 54 |
| Apr 2024 | 54 |
| May 2024 | 54 |
| Jun 2024 | 54 |
| Jul 2024 | 54 |
Emmaus Life Sciences other data
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 2000000 | 0 |
| May 2023 | 28700 | 0 |
| Aug 2023 | 2265 | 0 |
| Nov 2023 | 13344 | 0 |
| Dec 2023 | 0 | 38500 |
| Insider | Compensation |
|---|---|
| Dr. Yutaka Niihara M.D., M.P.H, M.P.H. (1960) Chairman & Chief Executive Officer | $385,000 |
Mr. Willis C. Lee M.S. (1960) Vice Chairman & Chief Operating Officer | $240,000 |
Mr. Yasushi Nagasaki CPA, CPA (1967) Chief Financial Officer | $240,000 |
-
What's the price of Emmaus Life Sciences stock today?
One share of Emmaus Life Sciences stock can currently be purchased for approximately $0.01.
-
When is Emmaus Life Sciences's next earnings date?
Unfortunately, Emmaus Life Sciences's (EMMA) next earnings date is currently unknown.
-
Does Emmaus Life Sciences pay dividends?
No, Emmaus Life Sciences does not pay dividends.
-
How much money does Emmaus Life Sciences make?
Emmaus Life Sciences has a market capitalization of 20.06M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 60.94% to 29.6M US dollars. Emmaus Life Sciences made a loss 3.73M US dollars in net income (profit) last year or $0.01 on an earnings per share basis.
-
What is Emmaus Life Sciences's stock symbol?
Emmaus Life Sciences, Inc. is traded on the OTC under the ticker symbol "EMMA".
-
What is Emmaus Life Sciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Emmaus Life Sciences?
Shares of Emmaus Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Emmaus Life Sciences's key executives?
Emmaus Life Sciences's management team includes the following people:
- Dr. Yutaka Niihara M.D., M.P.H, M.P.H. Chairman & Chief Executive Officer(age: 65, pay: $385,000)
- Mr. Willis C. Lee M.S. Vice Chairman & Chief Operating Officer(age: 65, pay: $240,000)
- Mr. Yasushi Nagasaki CPA, CPA Chief Financial Officer(age: 58, pay: $240,000)
-
How many employees does Emmaus Life Sciences have?
As Jul 2024, Emmaus Life Sciences employs 54 workers.
-
When Emmaus Life Sciences went public?
Emmaus Life Sciences, Inc. is publicly traded company for more then 25 years since IPO on 9 May 2000.
-
What is Emmaus Life Sciences's official website?
The official website for Emmaus Life Sciences is emmausmedical.com.
-
Where are Emmaus Life Sciences's headquarters?
Emmaus Life Sciences is headquartered at 21250 HAWTHORNE BOULEVARD, SUITE 800, Torrance, CALIFORNIA.
-
How can i contact Emmaus Life Sciences?
Emmaus Life Sciences's mailing address is 21250 HAWTHORNE BOULEVARD, SUITE 800, Torrance, CALIFORNIA and company can be reached via phone at +1 310 214 0065.
Emmaus Life Sciences company profile:
Emmaus Life Sciences, Inc.
emmausmedical.comOTC
58
Biotechnology
Healthcare
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Torrance, CALIFORNIA 90503
CIK: 0000822370
ISIN: US29137T1016
CUSIP: 29137T101
